WO2014160940A3 - Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques - Google Patents
Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques Download PDFInfo
- Publication number
- WO2014160940A3 WO2014160940A3 PCT/US2014/032177 US2014032177W WO2014160940A3 WO 2014160940 A3 WO2014160940 A3 WO 2014160940A3 US 2014032177 W US2014032177 W US 2014032177W WO 2014160940 A3 WO2014160940 A3 WO 2014160940A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- cancer
- treatment
- pyrrole
- fibrotic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000003176 fibrotic effect Effects 0.000 title abstract 3
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 title 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- 150000003577 thiophenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- -1 isotopic analog Substances 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
- C07D333/10—Thiophene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014240950A AU2014240950B2 (en) | 2013-03-29 | 2014-03-28 | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders |
CA2908505A CA2908505A1 (fr) | 2013-03-29 | 2014-03-28 | Composes de furane, pyrrole et thiophene lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques |
EP14772672.3A EP2978422A4 (fr) | 2013-03-29 | 2014-03-28 | Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques |
CN201480019528.1A CN105209037A (zh) | 2013-03-29 | 2014-03-28 | 用于治疗癌症、神经障碍和纤维化病症的脂类呋喃、吡咯和噻吩化合物 |
JP2016505591A JP6532860B2 (ja) | 2013-03-29 | 2014-03-28 | 癌、神経障害及び線維性障害の治療のための、脂質フラン、ピロール及びチオフェン化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361853163P | 2013-03-29 | 2013-03-29 | |
US61/853,163 | 2013-03-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014160940A2 WO2014160940A2 (fr) | 2014-10-02 |
WO2014160940A3 true WO2014160940A3 (fr) | 2014-12-31 |
Family
ID=51625685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/032177 WO2014160940A2 (fr) | 2013-03-29 | 2014-03-28 | Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques |
Country Status (7)
Country | Link |
---|---|
US (6) | US9371302B2 (fr) |
EP (1) | EP2978422A4 (fr) |
JP (1) | JP6532860B2 (fr) |
CN (2) | CN111285841A (fr) |
AU (1) | AU2014240950B2 (fr) |
CA (1) | CA2908505A1 (fr) |
WO (1) | WO2014160940A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014160940A2 (fr) | 2013-03-29 | 2014-10-02 | Avoscience, Llc | Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques |
US20170312246A1 (en) | 2016-04-27 | 2017-11-02 | Avoscience, Llc | Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis |
KR102221789B1 (ko) * | 2019-06-27 | 2021-03-02 | 재단법인대구경북과학기술원 | 2-펜틸퓨란을 유효성분으로 함유하는 퇴행성 뇌질환 치료용 조성물 |
CN110859836B (zh) * | 2019-11-29 | 2022-04-15 | 南京林业大学 | 灵菌红素在制备淋巴管肌瘤病细胞增殖抑制剂中的应用 |
CA3207296A1 (fr) * | 2021-01-06 | 2022-07-14 | The Penn State Research Foundation | Methodes et materiaux de traitement contre la perte de cheveux |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4427693A (en) * | 1981-08-05 | 1984-01-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines |
US6960594B2 (en) * | 1998-06-29 | 2005-11-01 | Shire Biochem Inc. | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer |
WO2007032591A1 (fr) * | 2005-09-13 | 2007-03-22 | Industry-Academic Cooperation Foundation, Yeungnam University | Composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propenone presentant une activite anti-angiogenique et une activite inhibitrice du cancer |
US7375105B2 (en) * | 2001-09-05 | 2008-05-20 | Smithkline Beecham P.L.C. | Pyridine substituted furan derivatives as Raf kinase inhibitors |
WO2008080986A1 (fr) * | 2006-12-28 | 2008-07-10 | Neuropharma, S.A. | Dérivés du furane, leur procédé de synthèse et leurs utilisations |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU33730B (en) * | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
CA1339784C (fr) | 1988-06-23 | 1998-03-31 | Shinya Inoue | Derives de l'acide pyrrolecarboxylique |
FR2678614A1 (fr) * | 1991-07-03 | 1993-01-08 | Pharmascience Lab | Compose presentant une activite en tant qu'inhibiteur de la collagenase et medicament le contenant. |
US5514709A (en) | 1993-10-25 | 1996-05-07 | Conkle & Olsten | Lipidic furans and retinol palmitate compositions useful for skin therapeutics |
US5468490A (en) * | 1993-10-25 | 1995-11-21 | Conkle & Olesten | Lipidic furans useful for skin therapeutics |
US6166003A (en) * | 1999-02-17 | 2000-12-26 | Lkt Laboratories, Inc. | Heterocyclic compounds for cancer chemoprevention |
FR2798667B1 (fr) | 1999-09-22 | 2001-12-21 | Pharmascience Lab | Procede d'extraction des composes furaniques et alcools gras polyhydroxyles de l'avocat, composition a base de et utilisation de ces composes en therapeutique, cosmetique et alimentaire |
US6734207B2 (en) * | 2001-04-20 | 2004-05-11 | Parker Hughes Institute | Cytotoxic compounds |
WO2004016106A1 (fr) | 2002-07-29 | 2004-02-26 | Laboratoires Expanscience | Procede d'obtention d'un insaponifiable d'avocat riche en lipides furaniques |
US20060018937A1 (en) | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20050004211A1 (en) * | 2003-06-30 | 2005-01-06 | Kaohsiung Medical University | Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds |
US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
EP1750695B1 (fr) | 2004-05-28 | 2010-03-31 | Laboratoires Expanscience | Utilisation d"alkyle furannes pour la preparation d'un medicament destine au traitement de l"obesite et pour le traitement cosmetique de la surcharge ponderale |
FR2870740B1 (fr) * | 2005-03-21 | 2008-06-13 | Expanscience Sa Lab | Utilisation d'alkyle furannes pour le traitement cosmetique de la cellulite |
FR2870742B1 (fr) | 2004-05-28 | 2008-03-14 | Expanscience Laboratoires Sa | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement du diabete, de l'obesite et pour le traitement cosmetique de la cellulite et de la surcharge ponderale |
WO2006004759A2 (fr) | 2004-06-29 | 2006-01-12 | Mcclellan Stephanie N | Compositions topiques anti-age et leurs methodes d'utilisation |
FR2889956B1 (fr) | 2005-08-30 | 2012-04-20 | Expanscience Lab | Utilisation d'au moins un 2-alkyle furane, a titre de principe actif depigmentant ou eclaircissant |
JP2008201003A (ja) | 2007-02-20 | 2008-09-04 | Canon Inc | インクジェット記録装置及びその記録ヘッド回復方法 |
EP2200611A4 (fr) | 2007-09-14 | 2010-09-22 | Biogen Idec Inc | Compositions et procédés de traitement de la leucoencéphalopathie multifocale progressive (lemp) |
US20120295965A1 (en) * | 2009-12-31 | 2012-11-22 | Huayun Deng | Fused thiophenes as dual inhibitors of egfr/vegfr and their use in the treatment of cancer |
WO2014160940A2 (fr) | 2013-03-29 | 2014-10-02 | Avoscience, Llc | Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques |
US20170312246A1 (en) | 2016-04-27 | 2017-11-02 | Avoscience, Llc | Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis |
-
2014
- 2014-03-28 WO PCT/US2014/032177 patent/WO2014160940A2/fr active Application Filing
- 2014-03-28 JP JP2016505591A patent/JP6532860B2/ja active Active
- 2014-03-28 US US14/229,130 patent/US9371302B2/en not_active Expired - Fee Related
- 2014-03-28 EP EP14772672.3A patent/EP2978422A4/fr not_active Withdrawn
- 2014-03-28 CN CN202010237994.4A patent/CN111285841A/zh not_active Withdrawn
- 2014-03-28 CA CA2908505A patent/CA2908505A1/fr not_active Abandoned
- 2014-03-28 CN CN201480019528.1A patent/CN105209037A/zh active Pending
- 2014-03-28 AU AU2014240950A patent/AU2014240950B2/en not_active Ceased
-
2016
- 2016-05-23 US US15/162,074 patent/US9814694B2/en active Active
-
2017
- 2017-10-12 US US15/782,535 patent/US10085962B2/en active Active
-
2018
- 2018-08-23 US US16/110,778 patent/US10525031B2/en active Active
-
2019
- 2019-12-19 US US16/721,638 patent/US11058663B2/en active Active
-
2021
- 2021-01-14 US US17/149,549 patent/US11833129B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4427693A (en) * | 1981-08-05 | 1984-01-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines |
US6960594B2 (en) * | 1998-06-29 | 2005-11-01 | Shire Biochem Inc. | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer |
US7375105B2 (en) * | 2001-09-05 | 2008-05-20 | Smithkline Beecham P.L.C. | Pyridine substituted furan derivatives as Raf kinase inhibitors |
WO2007032591A1 (fr) * | 2005-09-13 | 2007-03-22 | Industry-Academic Cooperation Foundation, Yeungnam University | Composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propenone presentant une activite anti-angiogenique et une activite inhibitrice du cancer |
WO2008080986A1 (fr) * | 2006-12-28 | 2008-07-10 | Neuropharma, S.A. | Dérivés du furane, leur procédé de synthèse et leurs utilisations |
Non-Patent Citations (2)
Title |
---|
"Toxicology and carcinogenesis studies of furan (CAS No. 110-00-9) in F344/N RATS and B6C3F1 mice (gavage studies).", NATIONAL TOXICOLOGY PROGRAM TECHNICAL REPORT SERIES NO. 402, January 1993 (1993-01-01), XP055289079, Retrieved from the Internet <URL:http://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr402.pdf> [retrieved on 20141015] * |
DATABASE PUBCHEM [online] 16 September 2004 (2004-09-16), "FURAN", XP055290826, accession no. NCBI Database accession no. CID 8029 * |
Also Published As
Publication number | Publication date |
---|---|
EP2978422A4 (fr) | 2017-04-05 |
CN105209037A (zh) | 2015-12-30 |
CN111285841A (zh) | 2020-06-16 |
JP6532860B2 (ja) | 2019-06-19 |
US10525031B2 (en) | 2020-01-07 |
JP2016515585A (ja) | 2016-05-30 |
US20200237709A1 (en) | 2020-07-30 |
US20140309274A1 (en) | 2014-10-16 |
AU2014240950B2 (en) | 2018-11-01 |
US20180050013A1 (en) | 2018-02-22 |
CA2908505A1 (fr) | 2014-10-02 |
AU2014240950A1 (en) | 2015-10-22 |
EP2978422A2 (fr) | 2016-02-03 |
US9814694B2 (en) | 2017-11-14 |
US20210137876A1 (en) | 2021-05-13 |
US11058663B2 (en) | 2021-07-13 |
WO2014160940A2 (fr) | 2014-10-02 |
US11833129B2 (en) | 2023-12-05 |
US10085962B2 (en) | 2018-10-02 |
US20160263080A1 (en) | 2016-09-15 |
US9371302B2 (en) | 2016-06-21 |
US20180360798A1 (en) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN09805A (fr) | ||
WO2014070991A3 (fr) | Composés antagonistes de la sélectine e et leurs procédés d'utilisation | |
EA201690962A1 (ru) | Составы | |
IN2014DN09804A (fr) | ||
WO2011106729A3 (fr) | Compositions pharmaceutiques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques. | |
WO2015095223A3 (fr) | Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci | |
WO2010017545A3 (fr) | Composés de triazole qui modulent l'activité hsp90 | |
EA201391615A1 (ru) | Дейтерированные потенциаторы cftr | |
WO2013158680A3 (fr) | Compositions et méthodes comprenant du célécoxib ou composés apparentés et du dextrométhorphane | |
WO2011127333A3 (fr) | Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques | |
MY187718A (en) | Pharmaceutical formulations | |
EA201491857A1 (ru) | АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ | |
MX2013012588A (es) | Inhibidores de cinasa. | |
WO2011047173A3 (fr) | Compositions pharmaceutiques à usage oral | |
WO2014160940A3 (fr) | Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques | |
EP3060220A4 (fr) | Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies | |
WO2014036502A8 (fr) | Composés de tétracyclines | |
SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
WO2014035846A3 (fr) | Composés azaindole substitué, leurs sels, leurs compositions pharmaceutiques et leurs procédés d'utilisation | |
WO2012103456A3 (fr) | Dérivés polycycliques de bêta-lactame pour le traitement du cancer | |
WO2014032019A3 (fr) | Composés et leurs procédés d'utilisation pour traiter des tumeurs | |
WO2011028737A8 (fr) | Compositions de bisphosphonate et procédés de traitement d'une insuffisance cardiaque | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
WO2015047982A3 (fr) | Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ces compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14772672 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2016505591 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2908505 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014240950 Country of ref document: AU Date of ref document: 20140328 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014772672 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14772672 Country of ref document: EP Kind code of ref document: A2 |